Drug intelligence / Profile preview

Omicron Inactivated COVID-19 Vaccine (Vero Cell)

Development stage
Phase 3
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The **Omicron Inactivated COVID-19 Vaccine (Vero Cell)** is an inactivated vaccine developed to protect against COVID-19 caused by the Omicron variant of SARS-CoV-2. It uses whole virions of the Omicron strain propagated in Vero cells—a continuous cell line derived from African green monkey kidney cells—then inactivated (typically with beta-propiolactone or formaldehyde) to preserve key antigens while eliminating infectivity. The mechanism involves intramuscular injection to induce neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 spike protein and other viral components, mimicking natural infection without causing disease. Primarily indicated for active immunization against symptomatic COVID-19 in adults and children, it was authorized in several countries including China, Indonesia, and others for booster use against Omicron subvariants.

Other names
omicron covid-19 vaccine (vero cell), inactivatedcovid-19 vaccine, inactivated, omicron strainsars-cov-2 antigen inhibitors drug (sinovac biotech)
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Omicron Inactivated COVID-19 Vaccine (Vero Cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omicron Inactivated COVID-19 Vaccine (Vero Cell).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call